1. Report Introduction 2. Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Market Overview at a Glance 2.1. Market Share Distribution of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 2017 2.2. Market Share Distribution of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 2028 3. Disease Background and Overview: Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM 4.3. Total Prevalent Patient Population of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM – By Countries 5. Epidemiology of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.1.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *Indication Specific 5.1.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *Indication Specific 5.1.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.1.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.4.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.4.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.4.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.4.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.5.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.5.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.5.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.5.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.6.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.6.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.6.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.6.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.7.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.7.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.7.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.7.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.8.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.8.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.8.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.8.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.9.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.9.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) * 5.9.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 5.9.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) : 7MM Market Analysis 12.1. 7MM Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 12.2. 7MM Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 12.3. 7MM Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products 13. Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States 13.1.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States 13.1.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany 13.2.1.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany 13.2.1.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France 13.2.2.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France 13.2.2.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy 13.2.3.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy 13.2.3.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain 13.2.4.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain 13.2.4.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United Kingdom 13.2.5.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan 13.3.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan 13.3.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight

Table 1: Total Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM Table 2: Total Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028) Table 4: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028) Table 5: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028) Table 6: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028) Table 7: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028) Table 8: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028) Table 9: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028) Table 10: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028) Table 11: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028) Table 12: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028) Table 13: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028) Table 14: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028) Table 15: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028) Table 16: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028) Table 17: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028) Table 18: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028) Table 19: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028) Table 20: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028) Table 21: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028) Table 22: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028) Table 23: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028) Table 24: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028) Table 25: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028) Table 26: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028) Table 27: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028) Table 28: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028) Table 29: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028) Table 30: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028) Table 31: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028) Table 32: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028) Table 33: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028) Table 34: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028) Table 35: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028) Table 36: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028) Table 37: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Table 42:7MM- Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 43:7MM- Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 44: United States-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Table 45: United States-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 46: United States-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 47: Germany-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Table 48: Germany-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 49: Germany-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 50: France-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Table 51: France-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 52: France-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 53: Italy-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Table 54: Italy-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 55: Italy-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 56: Spain-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Table 57: Spain-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 58: Spain-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 59:UK-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Table 60:UK-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 61:UK-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 62: Japan-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Table 63: Japan-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Table 64: Japan-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 1: Total Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM Figure 2: Total Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028) Figure 4: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028) Figure 5: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028) Figure 6: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028) Figure 7: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028) Figure 8: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028) Figure 9: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028) Figure 10: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028) Figure 11: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028) Figure 12: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028) Figure 13: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028) Figure 14: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028) Figure 15: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028) Figure 16: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028) Figure 17: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028) Figure 18: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028) Figure 19: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028) Figure 20: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028) Figure 21: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028) Figure 22: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028) Figure 23: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028) Figure 24: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028) Figure 25: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028) Figure 26: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028) Figure 27: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028) Figure 28: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028) Figure 29: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028) Figure 30: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028) Figure 31: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028) Figure 32: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028) Figure 33: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028) Figure 34: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028) Figure 35: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028) Figure 36: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028) Figure 37: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Figure 42:7MM- Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 43:7MM- Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 44: United States-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Figure 45: United States-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 46: United States-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 47: Germany-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Figure 48: Germany-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 49: Germany-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 50: France-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Figure 51: France-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 52: France-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 53: Italy-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Figure 54: Italy-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 55: Italy-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 56: Spain-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Figure 57: Spain-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 58: Spain-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 59:UK-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Figure 60:UK-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 61:UK-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 62: Japan-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028) Figure 63: Japan-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028) Figure 64: Japan-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)